RMD Share Price | ResMed, Inc. Stock Analysis & Recommendation

Q: How big is ResMed, Inc.?

Market Cap: As of Jun 18, ResMed, Inc. has a market capitalization of 47,132.87 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, ResMed, Inc. reported net sales of 5,021.53 million and a net profit of 1,313.26 million.Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 4,864.04 million and total assets of 6,872.39 million.

Q: What does ResMed, Inc. do?

Overview: ResMed, Inc. is a holding company engaged in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications for diagnosing, treating, and managing respiratory disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.Financial Snapshot: Most recent Net Sales: 1,292 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 365 Million (Quarterly Results - Mar 2025) Market cap: USD 47,132.87 Million (Large Cap)Key Metrics: P/E: 36.00 Dividend Yield: 2.65% Debt Equity: -0.04 Return on Equity: 23.58% Price to Book: 8.50Contact Details: Address: 9001 Spectrum Center Blvd, SAN DIEGO CA: 92123-1438 Tel: 1 858 7462400 Website: https://www.resmed.com/

Q: Is ResMed, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ResMed, Inc. has moved from fair to attractive, indicating a more favorable assessment of its market position. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 1.15, and a robust ROCE of 30.33%. In comparison to peers, ResMed's P/E ratio is slightly higher than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, but lower than DexCom, Inc. at 53.65, suggesting a competitive valuation within its industry.Despite recent underperformance against the S&P 500 over the past week and month, where it returned -1.44% and -1.33% respectively, ResMed has shown resilience with a year-to-date return of 17.23%, outperforming the index's 13.30%. This performance, combined with its attractive valuation metrics, reinforces the view that ResMed is positioned favorably in the market.

Q: Is ResMed, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for ResMed, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are both mildly bearish, while the monthly MACD remains bullish. The weekly Bollinger Bands indicate a bearish trend, contrasted by a mildly bullish monthly perspective. Daily moving averages show a mildly bullish stance. In terms of performance, ResMed has underperformed the S&P 500 over the past week and month, with returns of -3.21% and -5.36% compared to the S&P's gains of 1.92% and 2.32%, respectively. However, year-to-date, ResMed is slightly behind the S&P 500, with a return of 13.47% versus 15.47%. Overall, the mixed indicators suggest a cautious approach.

Results Declared: ResMed, Inc. has declared results on 30 Apr 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

436.2 k

Shareholding (Mar 2026)

FII

21.24%

Held by 425 FIIs

DII

51.32%

Held by 40 DIIs

Promoter

0.36%

How big is ResMed, Inc.?

22-Jun-2025

As of Jun 18, ResMed, Inc. has a market capitalization of $47.13 billion, with net sales of $5.02 billion and a net profit of $1.31 billion reported over the latest four quarters.

View full answer

What does ResMed, Inc. do?

22-Jun-2025

ResMed, Inc. develops and manufactures medical devices and software for respiratory disorders, with recent net sales of $1.29 billion and a market cap of $47.13 billion. Key metrics include a P/E ratio of 36.00 and a dividend yield of 2.65%.

View full answer

Who are in the management team of ResMed, Inc.?

22-Jun-2025

As of March 2022, the management team of ResMed, Inc. includes Dr. Peter Farrell (Non-Executive Chairman), Mr. Michael Farrell (CEO and Director), Mr. Ronald Taylor (Lead Independent Director), and Independent Directors Ms. Carol Burt, Mr. Jan De Witte, and Ms. Karen Drexler. They are responsible for the company's strategic direction and operations.

View full answer

Is ResMed, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, ResMed, Inc. is considered an attractive investment due to its undervaluation indicated by a P/E ratio of 36, a PEG ratio of 1.15, and a strong ROCE of 30.33%, despite recent underperformance against the S&P 500, as it has achieved a year-to-date return of 17.23%.

View full answer

Is ResMed, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, ResMed, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently, and suggesting a cautious investment approach.

View full answer

Compare ResMed, Inc. with Similar Stocks

Align Technology, Inc.Zimmer Biomet Holdings, Inc.Mettler-Toledo International, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 25.79%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.50 times

Healthy long term growth as Operating profit has grown by an annual rate 15.84%

The company has declared Positive results for the last 5 consecutive quarters

With ROCE of 30.33%, it has a attractive valuation with a 8.90 Enterprise value to Capital Employed

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 43,243 Million (Mid Cap)

P/E

29.00

Industry P/E

Dividend Yield

3.17%

Debt Equity

-0.12

Return on Equity

23.77%

Price to Book

6.84

Revenue and Profits:

Net Sales:

1,431 Million

(Quarterly Results - Mar 2026)

Net Profit:

399 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.83%

6 Months

-17.73%

1 Year

-15.45%

2 Years

-4.29%

3 Years

-10.69%

4 Years

2.4%

5 Years

6.01%

ResMed, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.79%

EBIT Growth (5y)

15.75%

EBIT to Interest (avg)

41.25

Debt to EBITDA (avg)

0.50

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

0.80

Tax Ratio

16.74%

Dividend Payout Ratio

22.30%

Pledged Shares

Institutional Holding

66.81%

ROCE (avg)

25.79%

ROE (avg)

21.53%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.84

EV to EBIT

23.03

EV to EBITDA

20.32

EV to Capital Employed

7.61

EV to Sales

7.88

PEG Ratio

1.34

Dividend Yield

3.17%

ROCE (Latest)

33.03%

ROE (Latest)

23.77%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 149 Schemes (27.07%)

Foreign Institutions

Held by 425 Foreign Institutions (21.24%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 10.82% vs 7.91% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 9.23% vs 21.46% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,431.40",
          "val2": "1,291.70",
          "chgp": "10.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "574.70",
          "val2": "478.20",
          "chgp": "20.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "3.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.20",
          "val2": "-0.10",
          "chgp": "2,300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "398.70",
          "val2": "365.00",
          "chgp": "9.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "353.30%",
          "val2": "330.00%",
          "chgp": "2.33%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 9.84% vs 10.95% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 37.19% vs 13.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,146.30",
          "val2": "4,685.30",
          "chgp": "9.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,923.20",
          "val2": "1,600.30",
          "chgp": "20.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.60",
          "val2": "60.10",
          "chgp": "-79.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "7.60",
          "val2": "-54.00",
          "chgp": "114.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,400.70",
          "val2": "1,021.00",
          "chgp": "37.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "327.90%",
          "val2": "295.40%",
          "chgp": "3.25%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

1,431.40

1,291.70

10.82%

Operating Profit (PBDIT) excl Other Income

574.70

478.20

20.18%

Interest

0.00

3.20

-100.00%

Exceptional Items

2.20

-0.10

2,300.00%

Consolidate Net Profit

398.70

365.00

9.23%

Operating Profit Margin (Excl OI)

353.30%

330.00%

2.33%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 10.82% vs 7.91% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 9.23% vs 21.46% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

5,146.30

4,685.30

9.84%

Operating Profit (PBDIT) excl Other Income

1,923.20

1,600.30

20.18%

Interest

12.60

60.10

-79.03%

Exceptional Items

7.60

-54.00

114.07%

Consolidate Net Profit

1,400.70

1,021.00

37.19%

Operating Profit Margin (Excl OI)

327.90%

295.40%

3.25%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 9.84% vs 10.95% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 37.19% vs 13.75% in Jun 2024

All Annual Results

Company CV

About ResMed, Inc.

ResMed, Inc.

Pharmaceuticals & Biotechnology

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.

Company Coordinates

Company Details

9001 Spectrum Center Blvd , SAN DIEGO CA : 92123-1438

Tel: 1 858 7462400

https://www.resmed.com/

Registrar Details